ST Germain D J Co. Inc. Sells 571 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
FierceBiotech13h
Gilead roars into JPM25, inking a $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...
Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?
As top pharma executives arrive in San Francisco, CA, to attend the J.P. Morgan Healthcare Conference next week, biotech dealmaking will be in focus as the annual event usually coincides with major ...
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...